|
⚲
|
| Renavance Pharma Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0001468422 |
| Sale | 2009-07-01 ($0.5 M Offered, $0.5 M Sold) |
| Fund | |
| Phone | 4153784099 |
| Address | 330 Deertrail Lane Mill Valley, 94941 |
| Source | [EDGAR] |
| Fund AUM and Sold ($k) |
|---|
| Fund Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Directors | 2011 - 2025 |
|---|---|
| John Donovan | |
| Mark Kessel | |
| Andrew Busser |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Next Frontier Ventures 18, a series of Assure Labs 2021, LLC
✚
|
0.0 | |
|
NextGen Abett LLC
✚
|
0.0 | |
|
NextGen Kasa LLC
✚
|
0.0 | |
|
NextGen Maven LLC
✚
|
0.0 | |
|
Next Level Marketing & Advertising Inc
✚
|
0.0 | |
|
Next Play Capital III, L.P.
✚
|
0.0 | |
|
Next Play Capital III Q, L.P.
✚
|
0.0 | |
|
Next Wave Residential Partners XI, LLC
✚
|
0.0 | |
|
Nexus Ventures VI, L.P.
✚
|
0.0 | |
|
Nextech V Oncology S.C.S., SICAV-SIF
✚
|
0.0 |